Syntec Optics extends collaboration on photonics for drug discovery
The company says its technology is supporting the integration of photonic systems into micro physiological systems, paving the way for real-time photonic biosensing that can improve the speed and accuracy of drug development
Syntec Optics, a provider of mission-critical products to advanced technology for manufacturers of defence, biomedical, and communications equipment, has announced its continued collaboration to enable the development of a novel photonic biosensing technology poised to transform drug discovery and testing.
Syntec Optics is focusing on providing critical optical manufacturing and sub-assembly processes to image laser light into its original equipment manufacturer’s (OEM) PICs, enabling the integration of photonic sensors into micro physiological systems (MPS). Scientists can now observe how human cells respond to drugs in real time, significantly improving the accuracy and speed of drug development, the company says.
According to Syntec Optics, its OEM’s groundbreaking approach addresses the critical challenge of high drug failure rates in clinical trials. Traditional testing methods often fail to predict human responses accurately. By replacing current animal models and lab tests with precise, real-time photonic biosensing, the company says that development timelines can be accelerated, and clinical trial costs can be lowered.
“Our advanced optical manufacturing capabilities to produce small and precise optics are essential for enabling photonic biosensing,” said Joel Lawther, programme manager at Syntec Optics. “By imaging laser light into our OEM's PICs, we are facilitating the creation of a powerful tool that will provide researchers with unprecedented insights into human cellular responses, starting with lung and brain tissue models.”
By enabling the precise optical integration required for photonic biosensing, Syntec Optics aims to play a vital role in shaping the future of medicine, helping to bring life-saving therapies to market faster.
